Ads
related to: early treatment diabetic retinopathy study
Search results
8 Tips to Prevent Diabetic Retinopathy
Verywell Health via Yahoo News· 2 years agoDiabetic retinopathy is a common complication of diabetes (including type 2 diabetes) that causes vision problems. This article will provide eight tips...
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
Zacks via Yahoo Finance· 1 year agoKodiakSciences KOD announced that the first patient has been treated in the early-stage study of...
1 in 4 People With Diabetes Have This Sight-Threatening Condition, Study Finds
Health via Yahoo News· 11 months agoDiabetes is a common condition that impacts more than 11% of the U.S. population, or 37.3 million...
Boehringer reports positive findings from diabetic macular ischemia trial
Clinical Trials Arena via Yahoo Finance· 3 weeks agoBoehringer Ingelheim has reported positive data from the HORNBILL Phase I/IIa clinical trial of the...
AI is upending eye exams for patients and providers—in a good way: ‘It’s been a godsend for us’
Fortune via Yahoo Finance· 2 months agoWith artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are...
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Zacks via Yahoo Finance· 2 months agoKodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is...
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
Zacks via Yahoo Finance· 5 months agoOcuphire Pharma’s OCUP lead retinal pipeline candidate is APX3330, a small-molecule inhibitor of...
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
Zacks via Yahoo Finance· 9 months agoIt was a busy week for the biotech sector, with quite a few important updates. Among these,...
Kodiak (KOD) Down as Late-Stage DME Studies Fail
Zacks via Yahoo Finance· 10 months agoKodiak Sciences’ KOD shares were down almost 45.9% on Jul 24, as it failed to meet the primary endpoint in two late-stage studies evaluating tarcocimab...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 2 weeks agoKodiak Sciences Inc. KOD reported first-quarter 2024 loss per share of 82 cents, narrower than the...
Ads
related to: early treatment diabetic retinopathy study
